Delayed donor red cell engraftment and prolonged red cell aplasia (PRCA) are well-recognized complications of major ABO-incompatible myeloablative and nonmyeloablative hematopoietic stem cell transplantation (HSCT). There is an intense debate about the impact on outcome, severity of hemolysis, association with graft-versus-host disease and survival after blood group-incompatible stem cell transplantation. Therefore, therapeutic strategies should be considered to avoid these possible complications. We present five patients, who received allogeneic HSCT from human leukocyte antigen-identical donors for hematological malignancies, which were treated with IgTherasorb s immunoadsorption (five treatments/week) to remove persisting incompatible isohemagglutinins. After a median of 17 treatments (range 9-25), all the patients became transfusion independent with the presentation of donor's blood group. No side effects occurred during treatment. Ig-Therasorb s immunoadsorption seems to be a promising therapeutic method for rapid, efficient and safe elimination for persisting isohemagglutinins for patients with PRCA after allogeneic hematological stem cell transplantation.
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Delayed donor red cell engraftment and prolonged red cell aplasia (PRCA) are well-recognized complications of major ABO-incompatible myeloablative and nonmyeloablative hematopoietic stem cell transplantation (HSCT). There is an intense debate about the impact on outcome, severity of hemolysis, association with graft-versus-host disease and survival after blood group-incompatible stem cell transplantation. Therefore, therapeutic strategies should be considered to avoid these possible complications. We present five patients, who received allogeneic HSCT from human leukocyte antigen-identical donors for hematological malignancies, which were treated with IgTherasorb s immunoadsorption (five treatments/week) to remove persisting incompatible isohemagglutinins. After a median of 17 treatments (range 9-25), all the patients became transfusion independent with the presentation of donor's blood group. No side effects occurred during treatment. Ig-Therasorb s immunoadsorption seems to be a promising therapeutic method for rapid, efficient and safe elimination for persisting isohemagglutinins for patients with PRCA after allogeneic hematological stem cell transplantation. Bone Marrow Transplantation (2003) 32, 1015-1019. doi:10.1038/sj.bmt.1704264 Keywords: red cell aplasia; stem cell transplantation; immunoadsorption Allogeneic hematopoietic stem cell transplantation (HSCT) has a high curative potential for various hematological diseases. Delayed donor red cell engraftment and prolonged red cell aplasia (PRCA) are well-recognized complications of major ABO-incompatible myeloablative and nonmyeloablative HSCT. There is an intense debate about the impact on outcome, severity of hemolysis, association with graft-versus-host disease and survival after blood group-incompatible stem cell transplantation. [1] [2] [3] Since blood group antigens are inherited independently of the human leukocyte antigen (HLA) complex, 4 ABO incompatibility between donor and recipient is observed in about 30% of HSCT. 5 Red cell incompatibility is classified according to whether donor's isohemagglutinins, isoantigens or both are incompatible with those of the recipient. Major ABO-incompatible HSCT recipients may experience delayed red cell recovery after transplantation because of persistent host isohemagglutinins that suppress donor's red cell hematopoiesis. 6 Several methods have been used for treatment of this complication: removal of ABO antibodies by large-volume plasmapheresis prior or after transplantation, 7 transfusion of donor-type red cells, 8 removal of anti-A and anti-B antibodies by immunoadsorption on immobilized blood group antigens, 9 erythropoietin (EPO) to enhance red cell production, 10 immunosuppression with glucocorticoids or antithymocyte globulin and treatment with rituximab.
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Removal of immunoglobulins with Ig-Therasorb s immunoadsorption is a novel method for the treatment of various hematologic and immunologic diseases, such as acquired coagulation factor inhibitors, dilated cardiomyopathy and the removal of anti-HLA antibodies prior to renal transplantation. 12, 13 We report our experience with Ig-Therasorb s immunoadsorption for the treatment of five patients with PRCA due to persisting isohemagglutinins after major ABO-incompatible HSCT.
Patients and methods

Patients
Five patients (four male, one female, median age 37.5 years (range 29-50 years)) with PRCA after major ABOincompatible HSCT were treated with Ig-Therasorb s immunoadsorption. Two patients had received transplants for chronic myelogenous leukemia, two patients for acute lymphoblastic leukemia and one patient for non-Hodgkin's lymphoma. Stem cell donors were HLA-identical siblings in all the patients. Conditioning therapy consisted of cyclophosphamide and total body irradiation in three and chemotherapy alone in two patients. In all the patients cyclosporin A (CSA) and a short course of methotrexate were used for graft-versus-host disease prophylaxis. In all the patients, blood group was O. The donor's blood group was A in four cases and B in one case. All the patients received supportive care including irradiated packed red blood cell (RBC) transfusions to maintain hemoglobin concentration higher than 8.0 g/dl and single-donor platelet transfusions to maintain platelet counts higher than 20 Â 10 9 /l as previously described. 6 Packed RBCs of blood group O were transfused first, followed by transfusion of donor-type blood group RBCs when the donor's blood group was demonstrable. Some clinical data from three patients have been published previously. 6 Blood group, Rhesus typing and hemagglutinin titers Rhesus typing and identification of complete and incomplete anti-RBC alloantibodies and direct antiglobulin testing were performed by standard methods. 14, 15 Commercial reagents (DiaMed-ID system, Cressiesur-Morat, Switzerland) were used according to the manufacturer's instructions. Titers of anti-A and anti-B hemagglutinins in case of blood group incompatibilty were determined before the start of the conditioning regimen, then weekly until discharge, and thereafter biweekly until stable RBC engraftment had occurred. Anti-A and anti-B isohemagglutinins were determined by titrating the patient's sera against suitable RBCs.
14 To document any treatment benefit of immunoadsorption, a relative hemagglutinin score was evaluated by using the DiaMed-ID microtyping system (results are given as strength of agglutination, rated 0-4). 15 All patients had peripheral blood and reticulocyte counts performed on a daily basis starting 7 days before HSCT until hematopoietic engraftment. Absolute neutrophil counts (ANCs) were calculated from leukocyte and differential counts. Engraftment was defined as an ANC of 0.5 Â 10 9 /l for 3 consecutive days, platelet counts of 30 Â 10 9 /l and independence of RBC transfusions.
Prolonged red cell aplasia
PRCA was defined as reticulocytopenia less than 30 Â 10 9 /l that lasted for more than 60 days after HSCT, the absence of RBC precursors in the bone marrow, and dependence on RBC transfusions after exclusion of RBC alloantibodies, hemolysis, viral or bacterial infection, or relapse in patients with myeloid and megakaryocytic regeneration after HSCT.
Immunoadsorption
Blood was drawn via a 15-gauge needle from a peripheral vein, and anticoagulated with a continuous infusion of citrate and sodium heparin. Plasma was separated from blood cells with the Autopheresis-C therapeutic plasma system (TPS; Baxter) and transferred into an AdsorptionDesorption Automate system (ADA system, Medicap, Ulrichstein, Germany). This system consists of two columns each containing 150 ml of sepharose coupled with polyclonal sheep antibodies to human immunoglobulins (Ig-Therasorb s , Plasmaselect, Teterow, Germany). In one adsorption cycle, 400-500 ml of plasma is alternately loaded onto one column, while the other column is regenerated. In a single treatment session, 14-20 cycles were performed, resulting in a total processed plasma volume of 7000-8000 ml in 3.5-4.0 h. After passing the column, the plasma was reinfused via a contralateral vein. Regeneration of columns was performed by protein elution, followed by washing cycles with phosphate-buffered saline and isotonic sodium chloride solution. Calcium gluconate was infused to avoid citrate-induced hypocalcemia. Two columns were assigned to one patient and stored under sterile conditions between immunoadsorption treatments. Five treatments per week were performed during the first 2 weeks, and then treatment intensity was reduced to four or three times a week until incompatible isohemagglutinins were no longer detectable and a significant rise of hemoglobin levels and reticulocyte counts was observed. No immunoglobulin concentrates were substituted during treatment.
Results
The median time for ANC recovery (more than 0.5 Â 10 9 /l) was 12 days (range 10-19 days). Platelet recovery (above 30 Â 10 9 /l without the need for further transfusions) was reached after a median of 14 days (range 12-22 days). RBC reconstitution did not occur at day 60 after HSCT in the described patients. Bone marrow aspiration showed normal myeloid and megakaryocytic lineage with absent erythroid cells. For GVHD prophylaxis, all patients were still under immunosuppression with CSA. As initial treatment of PRCA, EPO was given at a dose of 10 000 IU subcutaneously three times a week starting on day 30 after HSCT, continued during immunoadsorption, and was terminated when a significant rise in reticulocytes was observed. As treatment with EPO was without beneficial effect, two patients were treated with Ig-Therasorb s immunoadsorption immediately. In three patients, standard plasmapheresis was initiated before immunoadsorption without beneficial effect. At the beginning of Ig-Therasorb s immunoadsorption therapy, the median hemoglobin level was 7.5 g/dl (range 6.7-8.6 g/dl), the median reticulocyte counts was 8 Â 10 9 /l (range 5-15 Â 10 9 /l) and the patients were still dependent on RBC transfusions. All patients were in complete remission of their hematological disease at start 1260 to o195; patient 4: 675 to o195, patient 5: 652 to o195) as well as the IgM levels (patient 1: 55 to o30; patient 2: 158 to o30; patient 3: 87 to o30; patient 4: 55 to o30, patient 5: 46 to o30). In parallel, in all patients persisting isohemagglutinins could be removed completely after a median of 17 treatments (range 9-25), and the patients became transfusion independent. Table 1 shows isohemagglutinin titers before HSCT, and before and after immunoadsorption. Hemoglobin levels and reticulocyte counts increased to the normal range. Platelet counts did not decrease significantly during immunoadsorption. Figure 1 shows the time courses of all patients. During 
Discussion
PRCA may be a major problem after allogeneic ABOincompatible HSCT. Although RBC depletion is performed before major ABO-incompatible stem cell transplantation, PRCA occurs in about 16%. 6 Attempts to remove isohemagglutinins prior or immediately after HSCT can give rise to several problems due to technical or infectious reasons, or are badly tolerated if the patient is in poor condition. Since the incidence of PRCA is relatively low and some patients are able to clear the isohemagglutinins spontaneously, 4 a prophylactic treatment of all ABOincompatible allogeneic HSCT recipients is not justified. Other forms of treatment aim to remove the persisting isohemagglutinins after day 60 after HSCT, when the probability of spontaneous clearance is low. Various methods have been used to remove the persisting isohemagglutinins after HSCT. In three of our patients, standard plasmapheresis showed low efficacy of removing the circulating antibodies (Figure 1) . Infusion of donortype RBCs despite still measurable isohemagglutinins can lead to hemolysis with considerable side effects. Adsorption of whole blood or plasma on immobilized blood group antigens is an experimental procedure available only in single institutions. Reports of response to EPO are limited to patients whose isohemagglutinin titers had fallen to undetectable levels. 10 Only case reports exists about the use of glucocorticoids or antithymocyte globulin in this problem. Treatment with B-cell-directed antibodies such as rituximab may be an approach, but only one report has been published so far. 11 Our attempt to remove isohemagglutinins with Ig-Therasorb s , a device that has been successfully used for the removal of circulating antibodies in a variety of hematologic and immunologic diseases, 12, 13 was able to remove the antibodies effectively, to restore erythropoiesis and to render the patients transfusion independent. However, our observations suggest that a complete removal of the antibodies can only be achieved by treatment of large plasma volumes at daily intervals. In contrast to standard plasmapheresis, immunoadsorption allows nearly a complete clearance of circulating immunoglobulins of all types and subtypes (Ig1-Ig4), without the substitution of protein solutions or even fresh-frozen plasma during treatment, resulting only in a dilution of the circulating antibodies. Due to the limited number of patients, no data on comparing standard plasmapheresis and immunoadsorption are available so far. We think that the slight reduction of the antibody titers enables recovery of the donor's hematopoiesis, and a complete elimination of the isohemagglutinins occurs by excess of antigens due to the produced donor-type RBCs. As the number of patients treated with this device is small, no evidence-based recommendations could be given at the moment.
Although it is known that PRCA may be self-limited, therapy of PRCA seems to be necessary to avoid extensive transfusions of RBCs, and possible transfusion-associated risks like viral infections.
Our promising results with Ig-Therasorb s immunoadsorption should encourage the initiation of further studies to establish the best conditions of this therapy for patients with PRCA after major ABO-incompatible HSCT.
